Guru Ownership Trend
Guru Analysis for Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX), a key player in the Healthcare sector, continues to attract institutional attention.
As of Q1 2026, a total of 3 Super Investors (Gurus) hold positions in the company, with a combined stake valued at approximately $3.22 M.
Top institutional holders include Renaissance Technologies (RenTech) and Steven Cohen.
Institutional sentiment is currently Slightly Bearish. This is evidenced by a $236,435.6 net outflow during the quarter.
Recent activity highlights Steven Cohen who increased their stake by 90.9%. Conversely, Jefferies Group reduced exposure by 25.2%.
Key Holders
Top 5 by Value
Top 5 by Conviction
Recent Activity Breakdown (Q1 2026)
Guru Consensus (Q1 2026)
FAQs for Lineage Cell Therapeutics, Inc. (LCTX)
Major holders include Renaissance Technologies (RenTech) ($3.36 M), Steven Cohen ($480,894), Jefferies Group ($69,823). According to the latest reported data, 3 tracked investment managers collectively hold approximately 2.47 M shares.
According to the latest 13F reporting period, sentiment appears Bearish (Net Selling). There was a net outflow of $236,435.6, with 1 managers increasing positions and 2 managers reducing holdings.
During the most recent reporting period, 2 managers trimmed their positions, while 0 fully exited LCTX. The total reported sell value was $465,464.72.
Yes, 0 managers opened new positions in LCTX, and 1 increased their existing holdings. The total reported buy value was $229,029.12.